Oviva raises USD 21M to roll out digital diabetes treatment in Europe

VISCHER Legal Innovation Lab

In the VISCHER Innovation Lab, we not only work in the field of law, we also develop our solutions ourselves as far as possible from a technical point of view.

VISCHER Legal Innovation Lab

11 February 2020

Oviva raises USD 21M to roll out digital diabetes treatment in Europe.

The round was led by Swiss healthtech investor MTIP, joined by Earlybird as new investors. Existing investors AlbionVC, F-Prime Capital, Eight Roads Ventures and Partech all participated. Oviva offers an evidence-based digital solution to stop the progression of reverse Type 2 diabetes and obesity-related conditions. Patients receive tailored nutrition advice and personalised coaching via their phones.

VISCHER advised the new investors in this financing round. The team was led by Dr. Matthias Staehelin (Corporate / M&A) and included Nadia Tarolli (Tax), Luzius Zumstein (Corporate / M&A), Sebastian Flückiger and Pauline Pfirter (Corporate / M&A).

Press release